ProSensa B.V. and GlaxoSmithKline Initiate Development of Four Additional Products Under Existing Alliance in Duchenne Muscular Dystrophy

Published: Jun 23, 2010

LEIDEN, Netherlands--(BUSINESS WIRE)--Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa’s “exon skipping” platform and the ongoing relationship.

Back to news